European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
PDF) Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment
Adalimumab | ECCO E-Guide
Managing complex perianal disease after anti-TNF failure: Where to go next? - ScienceDirect
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients | Scientific Reports
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy - Gastroenterology
European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
![PDF] Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/434bc5078bbc62a1a4782f27592fcf28f239679e/8-Table2-1.png "PDF] Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. | Semantic Scholar")
PDF] Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. | Semantic Scholar
Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
Frontiers | Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
ECCO-EFCCA Patient Guidelines on Crohn's Disease (CD)
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study - The Lancet Gastroenterology & Hepatology
